- Clinical Trials
- April 2024
- 40 Pages
Global
From €1189EUR$1,250USD£999GBP
- Report
- January 2025
- 78 Pages
Global
From €3500EUR$3,943USD£3,046GBP
- Report
- March 2025
- 50 Pages
Global
From €2520EUR$2,650USD£2,119GBP
- Report
- March 2025
- 50 Pages
Global
From €2520EUR$2,650USD£2,119GBP
Betahistine is a medication used to treat symptoms of vertigo, a condition characterized by a sensation of spinning or whirling. It is classified as a histamine agonist, meaning it works by stimulating the release of histamine, a neurotransmitter that helps regulate balance and coordination. Betahistine is used to treat Meniere's disease, a disorder of the inner ear that can cause vertigo, hearing loss, and tinnitus. It is also used to treat vestibular neuritis, a condition that causes vertigo due to inflammation of the vestibular nerve.
Betahistine is a part of the Central Nervous System Drugs market, which includes medications used to treat neurological disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, and multiple sclerosis. These drugs are used to improve cognitive function, reduce seizures, and manage symptoms of neurological disorders.
Companies in the Betahistine market include Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline plc, Novartis AG, and Sanofi S.A. Show Less Read more